Ann: AML patient achieves Complete Response in CHM CORE-NK trial, page-62

Ok, let's see what the trial data will show. That's when the value should be determined.

It is just strange that nobody has any idea at this stage if iNKT will deliver or not and yet, the current trialed techs such as NK, CF33, Azer-Cel, B-Cell Vaccines, RAD's isotopes get valued just a tiny fraction of ALA despite their remarkable results.

Time will tell. But I can't argue with the fact that the financial management at ALA is a lot better than Hopper's way of self-destruction. And the continuation of the suspension isn't helping either.

GLTA